循环肿瘤细胞在肺癌精准医疗中的研究进展  

Research progress of circulating tumor cells for precision medicine in lung cancer

作　　者：李欣[1] 周倩(综述)[1] 唐小葵(审校)[1] Xin Li;Qian Zhou;Xiaokui Tang(Department of Respiratory and Critical Medicine,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院呼吸与危重症医学科,重庆市400016

出　　处：《中国肿瘤临床》2021年第20期1071-1074,共4页Chinese Journal of Clinical Oncology

摘　　要：肺癌是最常见的恶性肿瘤,也是癌症死亡的主要原因。循环肿瘤细胞(circulating tumor cells,CTCs)是从原发病灶或转移病灶脱落到外周血的肿瘤细胞,可在远处播散并引发肿瘤转移。现CTCs的研究已逐渐深入分子层面,CTCs携带的潜在临床信息也进一步被开发,在指导治疗、揭示转移机制、评估程序性细胞凋亡配体1(programmed cell death-ligand 1,PD-L1)表达等方面有巨大的潜在临床价值。本文就CTCs在肺癌精准医疗中的研究进展进行综述,并探讨CTCs与循环游离DNA(circulating free DNA,cfDNA)检测在肺癌中的互补意义,以期为肺癌的临床检测及个体化治疗提供新思路。Lung cancer is the most commonly diagnosed malignancy and a leading cause of cancer death.Circulating tumor cells(CTCs)are tumor cells initially shed from the primary tumor that can spread to distant organs where they may trigger metastasis.CTCs have recently gained immense attention wherein they have been studied up to the molecular level.The clinical information carried by the CTCs offers great potential to guide treatment,reveal the mechanisms underlying metastasis,and to assess programmed cell death-ligand 1(PD-L1)expression.In this review,we summarize the clinical significance of CTCs in the development of precision medicine for lung cancer.Moreover,the significance of CTCs and circulating-free DNA(cfDNA)is also discussed for potential clinical application in lung cancer,aiming to provide new insights into clinical detection and personalized therapy.

关 键 词：循环肿瘤细胞 肺癌 程序性细胞凋亡配体-1 循环游离 DNA 

分 类 号：R734.2[医药卫生—肿瘤]